When evaluated for treatment outcomes, BRAF-V600E positive-patients treated with BRAF-specific inhibitor dabrafenib had prompt resolution of MAS-HLH signs and symptoms than the second-line chemotherapy. Here, BRAF is linked to hemophagocytic syndrome.